SpeeDx and Cepheid Announce European Distribution Partnership

Strategic commercial partnership in key European markets with Cepheid.

SYDNEY, AUSTRALIA–(Marketwired – Jun 8, 2017) – SpeeDx Pty, Ltd., a developer of innovative molecular diagnostic solutions, today announced an agreement with Cepheid for distribution of its PlexPCR™ and ResistancePlus™ molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the UK, will increase coverage for the market-leading ResistancePlus™ MG test, the first CE-IVD test for the sexually transmitted infection (STI) Mycoplasma genitalium (MG) to combine detection with testing for azithromycin resistance.

Read the full article here